142 related articles for article (PubMed ID: 34003301)
1. Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.
Dozin B; Carbotti G; Roncella S; Ferro P; Dessanti P; Canessa PA; Ferrini S; Fabbi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3349-3355. PubMed ID: 34003301
[TBL] [Abstract][Full Text] [Related]
2. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
3. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
4. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
[TBL] [Abstract][Full Text] [Related]
5. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
6. The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma.
Asciak R; Kanellakis NI; Bibby A; Kidd A; Gerry S; Mercer R; Maskell N; Blyth KG; Fsadni P; Montefort S; Psallidas I; Rahman NM
Chest; 2021 Nov; 160(5):1925-1933. PubMed ID: 34119515
[TBL] [Abstract][Full Text] [Related]
7. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
8. High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.
Ollila H; Paajanen J; Wolff H; Ilonen I; Sutinen E; Välimäki K; Östman A; Anttila S; Kettunen E; Räsänen J; Kallioniemi O; Myllärniemi M; Mäyränpää MI; Pellinen T
J Pathol Clin Res; 2021 Sep; 7(5):482-494. PubMed ID: 33955203
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
Blondy T; d'Almeida SM; Briolay T; Tabiasco J; Meiller C; Chéné AL; Cellerin L; Deshayes S; Delneste Y; Fonteneau JF; Boisgerault N; Bennouna J; Grégoire M; Jean D; Blanquart C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581053
[TBL] [Abstract][Full Text] [Related]
10. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
11. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.
Suzuki K; Kadota K; Sima CS; Sadelain M; Rusch VW; Travis WD; Adusumilli PS
Cancer Immunol Immunother; 2011 Dec; 60(12):1721-8. PubMed ID: 21769693
[TBL] [Abstract][Full Text] [Related]
12. Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.
Barsky AR; Ahern CA; Venigalla S; Verma V; Anstadt EJ; Wright CM; Ludmir EB; Berlind CG; Lindsay WD; Grover S; Cengel KA; Simone CB
Clin Lung Cancer; 2020 Nov; 21(6):e583-e591. PubMed ID: 32611504
[TBL] [Abstract][Full Text] [Related]
13. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.
Zhang S; Zhang Y; Feng W; Shi Z; Shi H; Zhang Y
Thorac Cancer; 2021 Dec; 12(24):3304-3309. PubMed ID: 34704370
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification.
Urso L; Silic-Benussi M; Boscolo A; Lorenzi M; Bonanno L; Lunardi F; Guarneri V; Calabrese F; Rea F; Conte P; Pasello G
Cytokine; 2021 Oct; 146():155622. PubMed ID: 34153874
[TBL] [Abstract][Full Text] [Related]
15. T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions.
Okamoto M; Hasegawa Y; Hara T; Hashimoto N; Imaizumi K; Shimokata K; Kawabe T
Chest; 2005 Dec; 128(6):4030-5. PubMed ID: 16354877
[TBL] [Abstract][Full Text] [Related]
16. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
17. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
[TBL] [Abstract][Full Text] [Related]
18. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
Gutierrez-Sainz L; Cruz P; Martinez-Recio S; Higuera O; Esteban-Rodriguez MI; Arias-Lotto F; Gonzalez RA; De Castro-Carpeño J
Clin Transl Oncol; 2021 Oct; 23(10):2030-2035. PubMed ID: 33837910
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
